	US 12,329,792 B2
	Airway medicaments
David S. Harburger, Waltham, MA (US); and Prashant Girinath, Arlington, MA (US)
Assigned to Trench Therapeutics, Inc., Portola Valley, CA (US)
Filed by Trench Therapeutics, Inc., Portola Valley, CA (US)
Filed on Nov. 12, 2021, as Appl. No. 17/525,328.
Application 17/525,328 is a continuation of application No. PCT/US2021/034464, filed on May 27, 2021.
Claims priority of provisional application 62/704,770, filed on May 28, 2020.
Prior Publication US 2022/0072066 A1, Mar. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/747 (2015.01); A61K 35/00 (2006.01); A61K 35/741 (2015.01); A61M 15/00 (2006.01); A61M 15/08 (2006.01)

CPC A61K 35/747 (2013.01) [A61K 35/741 (2013.01); A61K 2035/115 (2013.01); A61M 15/009 (2013.01); A61M 15/08 (2013.01)]

10 Claims

1. A pharmaceutical composition, wherein the pharmaceutical composition comprises:

a live, purified population of bacteria comprising:

at least three different strains of Dolosigranulum pigrum; and

a strain of Corynebacterium pseudodiphtheriticum, wherein the strain of Corynebacterium pseudodiphtheriticum and the at least three different strains of Dolosigranulum pigrum are present in an amount sufficient for reduction in nasal cavity abundance of Staphylococcus aureus of a subject upon administration of the pharmaceutical composition as compared to nasal cavity abundance of Staphylococcus aureus of the subject prior to administration; and

a pharmaceutically acceptable excipient,

wherein the live, purified population of bacteria is lyophilized and present in a total amount of at least 10 3 CFU.